Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Taking A Closer Look At Talecris/Grifols Merger; HIGPA Voices Concerns

Executive Summary

The Federal Trade Commission has requested further information from both Talecris Biotherapeutics and Grifols in relation to the two companies' proposed merger

You may also be interested in...



Octapharma Expects To Have Octagam Back On the Market By Year's End

The company withdraws its IVIG Octagam 5% from the U.S. market following increased reports of thromboembolic events; it is challenging EMA's recommendation to withdraw the 10% formulation in Europe.

Octapharma Expects To Have Octagam Back On the Market By Year's End

The company withdraws its IVIG Octagam 5% from the U.S. market following increased reports of thromboembolic events; it is challenging EMA's recommendation to withdraw the 10% formulation in Europe.

Talecris Tries Merger Route Again; Plans Combination With Spain's Grifols

Deal would increase Talecris' plasma-collection capabilities while providing an exit to VC backer Cerberus.

Related Content

Topics

UsernamePublicRestriction

Register

PS052562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel